Immunotherapy for Mesothelioma — What Changed, and Who It Is For

Fewer people than the guidelines make it sound. Immunotherapy is a recognised first treatment for pleural mesothelioma that cannot be removed by surgery, but four things have to be true before it can start, and in India the first of them is where most patients stall.

The diagnosis has to be confirmed on tissue. Fluid drained from around the lung and examined under the microscope is often not enough. Mesothelioma is confirmed on a biopsy, usually taken at thoracoscopy or under image guidance, with immunohistochemistry to separate it from cancers that have spread to the pleura from elsewhere. Without that report, immunotherapy is not started, and a large number of people reach an oncologist with a chest drain and a suspicion rather than a diagnosis.

The disease has to be unresectable. That is the setting in which first-line immunotherapy has been studied. Where surgery is being considered at a specialist centre, the sequence of treatment is a separate discussion.

You have to be well enough. Mesothelioma is frequently found late, after months of breathlessness and weight loss blamed on something else. Someone who is bed-bound, or who is struggling with an uncontrolled effusion, may need the fluid managed and their strength recovered before any systemic treatment is safe. For some, that point is never reached, and saying so is part of an honest consultation.

Your immune system has to tolerate it. Active autoimmune disease, an organ transplant on immunosuppressive drugs, or ongoing high-dose steroids can make checkpoint inhibitor treatment unsuitable or higher-risk. These drugs release a brake on the immune system, so an immune system that is already over-active is a real obstacle.

This page describes pleural mesothelioma, which arises in the lining of the lung. Mesothelioma of the abdominal lining (peritoneal mesothelioma) is a different situation with a much smaller evidence base and a different standard approach. Nothing here decides eligibility — that rests on the biopsy report, the extent of disease and overall fitness, read together by a medical oncologist.

Yes, in a way that is unusual for this disease: it changed what the first treatment is. A randomised phase III trial, CheckMate 743, compared two checkpoint inhibitors given together against standard chemotherapy as the first treatment for unresectable pleural mesothelioma, and reported a benefit for the immunotherapy combination. It was published in The Lancet in 2021.

That matters because of what came before it. For roughly two decades, one chemotherapy combination was the only systemic treatment with randomised evidence behind it in mesothelioma. Very little moved. A first-line result that beat that combination is the single most significant development this disease has had, and it is why a rare cancer with a poor outlook now has an immunotherapy page at all.

The combination studied was dual checkpoint blockade: an antibody against PD-1 given with an antibody against CTLA-4. The two act on different brakes, which is why the pair does more than either alone, and also why the side-effect burden is higher than with a single agent. ASCO's updated pleural mesothelioma guideline, published in 2025, recommends this combination as a first-line option.

The benefit is not spread evenly, and this is the part worth arguing about in clinic. Mesothelioma comes in three histological subtypes. In non-epithelioid disease — sarcomatoid and biphasic — which has historically responded poorly to chemotherapy, the case for dual immunotherapy is strongest and most consistently reported. In epithelioid disease, chemotherapy remains a reasonable comparator, and choosing between them is a genuine discussion rather than a formality.

Effective does not mean it works for everyone, and no honest page can promise otherwise. Some patients respond, some do not, and mesothelioma is rarely removed completely by any treatment. The realistic aim of systemic treatment here is to control the disease for as long as possible and to keep symptoms manageable.

Both are recognised first-line options for unresectable pleural mesothelioma. Read the table across, then take the last two rows to your consultation.

Summarised from the ASCO pleural mesothelioma guideline update and published randomised trial reports current as of August 2026. No survival figure is quoted anywhere on this page. A number taken out of its trial population tells an individual patient almost nothing, and mesothelioma statistics are quoted online more carelessly than most.

Chemotherapy remains a proper first-line option, and it is not the only alternative. A platinum drug given with an antifolate drug has randomised evidence going back roughly two decades and long real-world experience. In epithelioid mesothelioma it is a reasonable comparator to dual immunotherapy rather than a fallback.

A middle path exists as well. Chemotherapy given together with a single anti-PD-1 antibody has been tested against chemotherapy alone in a separate randomised trial and is recognised in current guidance as another first-line option. It carries a lower immune side-effect burden than the two-antibody combination, which matters for a patient who is frail or who has a borderline autoimmune history.

Surgery has a narrow and contested place. Operations to remove the pleura are offered only at specialist centres to carefully selected patients, and a large randomised trial reported in 2024 questioned whether adding extended surgery to chemotherapy helps at all. If surgery is being proposed, it is entirely reasonable to ask which trial evidence supports it in your situation.

Some of the most useful treatment in mesothelioma is not aimed at the tumour. Fluid collecting around the lung is the usual cause of breathlessness, and draining it and then preventing it from returning — with talc pleurodesis or an indwelling pleural catheter that can be drained at home — often does more for day-to-day life than any drug. Radiotherapy can settle localised chest-wall pain. Early involvement of a palliative care team improves symptom control alongside active treatment, not instead of it.

Two options are commonly left unsaid. Clinical trials in mesothelioma exist and are worth asking about; this page is informational and cannot promise anyone a place in one. And choosing not to have systemic treatment, with full symptom control instead, is a legitimate decision for someone frail or unwilling to accept the side effects. An oncologist who cannot set that option out alongside the others is not giving you a real choice.

At CION, immunotherapy and chemotherapy are administered as day care at our centres. Response-assessment CT and PET-CT imaging is coordinated at partner imaging centres rather than performed in-house.

None of them. There is no biomarker test that selects patients for immunotherapy in mesothelioma. PD-L1 is used as a gate in some other cancers. It is not used that way here, and a low or absent PD-L1 result is not a reason you have been refused treatment.

What does the work instead is the histological subtype named on the biopsy report. That is why an adequate tissue sample matters more in mesothelioma than any molecular panel, and why a diagnosis made on drained fluid alone is often sent back for a proper biopsy.

Ask for the wording of the histopathology report rather than a verbal summary. Subtype, and whether the diagnosis rests on tissue or on fluid, are the two lines that change what happens next.

• Is the diagnosis on tissue, and which subtype does it name? Epithelioid, sarcomatoid or biphasic. This one line moves the first-line recommendation more than anything else on the report.
• Is the disease being called resectable or unresectable, and who decided? First-line immunotherapy has been studied in unresectable disease. If surgery is on the table, ask which specialist centre and which evidence supports it.
• What is being done about the fluid? Breathlessness in mesothelioma is usually the effusion, not the tumour mass. Pleurodesis or a drainable catheter often improves daily life faster than any systemic treatment.
• Have you been screened for an autoimmune condition or steroid use? Dual checkpoint blockade carries a higher immune side-effect burden than a single agent, and an existing autoimmune history changes the risk calculation meaningfully.
• What is the plan if the first assessment scan is disappointing? Ask at the start rather than later. Knowing there is a defined next step makes the first decision easier to take, not harder.

• For the rare cancer with the highest reported response to checkpoint inhibitors, and why a viral cause makes a tumour easier for the immune system to see, read Immunotherapy for Merkel Cell Carcinoma.
• If you want the longest-standing example of checkpoint inhibitors working reliably in a blood cancer, Immunotherapy for Hodgkin Lymphoma covers a very different disease treated on the same principle.
• The picture is more mixed in the lymphomas that are not Hodgkin — Immunotherapy for Non-Hodgkin Lymphoma explains where it helps and where it does not.
• For how immunotherapy is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Unsure how any of this applies to a specific report? Book a free consultation and a medical oncologist will read it with you.